Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Marie Hjälm Eriksson"'
Autor:
Alessio Crippa, Bram De Laere, Andrea Discacciati, Berit Larsson, Jason T. Connor, Erin E. Gabriel, Camilla Thellenberg, Elin Jänes, Gunilla Enblad, Anders Ullen, Marie Hjälm-Eriksson, Jan Oldenburg, Piet Ost, Johan Lindberg, Martin Eklund, Henrik Grönberg
Publikováno v:
Trials, Vol 21, Iss 1, Pp 1-10 (2020)
Abstract Background Multiple therapies exist for patients with metastatic castration-resistant prostate cancer (mCRPC). However, their improvement on progression-free survival (PFS) remains modest, potentially explained by tumor molecular heterogenei
Externí odkaz:
https://doaj.org/article/069d67da38134fbe9cff562b1524321c
Autor:
Charlotte Alverbratt, Hanna Vikman, Marie Hjälm Eriksson, Pär Stattin, Ingela Franck Lissbrant
Publikováno v:
Scandinavian Journal of Urology. 56:95-101
Background Patients with advanced prostate cancer (PCa) typically undergo numerous lines of treatment leading to large amounts of information in Electronic Health Records (EHRs). The Patient-overview Prostate Cancer (PPC) presents clinical informatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66738d9712e10d0e6a83ee22c3d2f3fe
https://doi.org/10.1080/21681805.2021.2014561
https://doi.org/10.1080/21681805.2021.2014561
Autor:
Marie Hjälm-Eriksson, Hemming Johansson, Enrique Castellanos, Göran Lundell, Yvonne Brandberg, Bo Lennernäs, Sten Nilsson, Anders Ullén
Publikováno v:
Acta Oncologica. 60:1301-1307
BACKGROUND AND PURPOSE To analyse the cumulative incidence of any failure (AF), prostate cancer-specific failure (PCSF), any death (AD), prostate cancer-specific death (PCSD), and local control in 2387 men with prostate cancer (PC), consecutively tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57514e9cf925d76c46523fa70496133b
https://doi.org/10.1080/0284186x.2021.1953706
https://doi.org/10.1080/0284186x.2021.1953706
Autor:
Suzanne Kilany, Ingela Franck Lissbrant, Karin Fagerlund, Johanna Svensson, Pär Stattin, Oskar Gauffin, Marie Hjälm-Eriksson
Publikováno v:
Scandinavian Journal of Urology. 55:1-8
To investigate time spent in hormone-sensitive and castration-resistant disease states in men with advanced prostate cancer in Sweden, and the associated health economic impact.Registry study (NCT03619980) of the Prostate Cancer data Base Sweden with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::459a0193d234902ffda856976c7a4faf
https://doi.org/10.1080/21681805.2020.1851762
https://doi.org/10.1080/21681805.2020.1851762
Autor:
Marie, Hjälm-Eriksson, Anders, Ullén, Sten, Nilsson, Hemming, Johansson, Josef, Nilsson, Enrique, Castellanos, Yvonne, Brandberg
The aim of this cross-sectional study was to investigate long-term health-related quality of life (HRQoL) in men with prostate cancer treated 2002–2008 with external beam radiotherapy (EBRT) combined with high dose-rate brachytherapy (HDRBT), Cohor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70760148c29ec875d486b98a5ba983b6
Autor:
Miikka, Lehtonen, Jorma, Sormunen, Marie, Hjälm-Eriksson, Camilla, Thellenberg-Karlsson, Teppo, Huttunen, Claes, Ginman, Pirkko-Liisa, Kellokumpu-Lehtinen
Publikováno v:
Anticancer research. 42(1)
The goal of this study was to investigate whether health-related quality of life (HRQoL) was affected in patients with high- or intermediate-risk localized prostate cancer treated with docetaxel following radiation therapy (RT).A total of 376 patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0393c15277f6bf095debb80fdd79978d
https://pubmed.ncbi.nlm.nih.gov/34969712
https://pubmed.ncbi.nlm.nih.gov/34969712
Autor:
Erin E. Gabriel, Jason T. Connor, Gunilla Enblad, Johan Lindberg, Martin Eklund, Anders Ullén, Berit Larsson, Elin Jänes, Alessio Crippa, Camilla Thellenberg, Henrik Grönberg, Piet Ost, Marie Hjälm-Eriksson, Jan Oldenburg, Bram De Laere, Andrea Discacciati
Publikováno v:
Trials
Trials, Vol 21, Iss 1, Pp 1-10 (2020)
TRIALS
Trials, Vol 21, Iss 1, Pp 1-10 (2020)
TRIALS
Background Multiple therapies exist for patients with metastatic castration-resistant prostate cancer (mCRPC). However, their improvement on progression-free survival (PFS) remains modest, potentially explained by tumor molecular heterogeneity. Sever
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ccc2e0c7d8478348d82545a934be5a1
https://doi.org/10.1186/s13063-020-04515-8
https://doi.org/10.1186/s13063-020-04515-8
Publikováno v:
Scandinavian journal of urology. 54(3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7d9063e900fef717196df9386e2171b6
https://pubmed.ncbi.nlm.nih.gov/32363988
https://pubmed.ncbi.nlm.nih.gov/32363988
Autor:
Pirkko-Liisa Kellokumpu-Lehtinen, Marie Hjälm-Eriksson, Claes Ginman, Teppo Huttunen, Ann-Fofie Fransson, Lennat Åström, Lars Franzén, Camilla Thellenberg-Karlsson, Markku J Leskinen, Mihalj Zeke
Publikováno v:
European Urology. 78:e241-e242
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5e5987904cb6d9c9dab945615af1a739
https://doi.org/10.1016/j.eururo.2020.08.035
https://doi.org/10.1016/j.eururo.2020.08.035
Autor:
Lars Franzén, Lennart Åström, Teppo Huttunen, Marie Hjälm-Eriksson, Camilla Thellenberg-Karlsson, Mihalj Zeke, Pirkko-Liisa Kellokumpu-Lehtinen, Claes Ginman, Markku J Leskinen, Ann-Sofie Fransson
Publikováno v:
European urology. 76(6)
Background Docetaxel combined with androgen deprivation therapy (ADT) has improved patient survival for advanced prostate cancer (PCa). Objective This randomised trial aimed to evaluate whether six courses of docetaxel improved biochemical disease–
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4432612712d4d803de04ebca4cd7b52b
https://pubmed.ncbi.nlm.nih.gov/32893063
https://pubmed.ncbi.nlm.nih.gov/32893063